Thyroid Eye Disease: Updates on Comprehensive Management*

Course Instructions

To obtain CME credit for this activity, please view the webcast, consult referenced sources as necessary, and complete the posttest and evaluation online at Upon completion, a certificate will be made available immediately.

Release Date: April 10, 2024

Expiration Date: August 31, 2024 (Note: After August 31, 2024, this webcast will be available on until April 30, 2025)

Activity Description and Purpose

This CME/CE webcast is designed for clinicians seeking to enhance their understanding and management of thyroid eye disease (TED). Featuring experts Drs Andrew G. Lee and Prem S. Subramanian, this educational activity provides participants with a holistic view of TED, from pathophysiology and epidemiology to diagnosis, and delves into the critical aspects of TED, including the latest clinical data for developing individualized treatment plans. Participants will engage in an in-depth exploration of the adverse effects associated with current treatments and the importance of a multidisciplinary approach to patient care via lectures, case studies, and panel discussions. The desired results of this activity are for participants to identify diagnostic criteria for TED, develop individualized treatment plans based on current clinical data, review management strategies for hyperglycemia and hearing loss associated with insulin-like growth factor 1 receptor antagonists, and recognize the multidisciplinary team's role in TED management.

Target Audience

This educational activity is intended for neuro-ophthalmologists and other ophthalmologists treating thyroid eye disease.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify diagnostic criteria that are critical for identifying patients with thyroid eye disease
  • Develop individualized treatment plans for patients with thyroid eye disease according to the latest clinical data
  • Review strategies to manage hyperglycemia and hearing loss in patients with thyroid eye disease receiving insulin-like growth factor 1 receptor antagonists
  • Recognize the roles and responsibilities of the multidisciplinary care team in thyroid eye disease management

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Peer Reviewer

Hadi Kaakour, MD, MS, was an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement


 MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Amgen Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at

To view the MedEdicus privacy policy, visit


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 314b